Story
Data Analytics Stocks Offer Deepest Value in Software Sector, Analysis Finds

Summary
An analysis of 191 US-listed software companies shows the data analytics subsector is trading at a significant discount to infrastructure and SaaS peers, driven by concerns over AI disruption and the ad-tech market.
The data analytics subsector of the software market currently presents the most compelling valuation case for investors, trading at a significant discount to both infrastructure software and business application SaaS peers. An analysis by Investing.com of 191 U.S.-listed software firms with market caps over $2 billion reveals clear valuation gaps between the industry's primary segments.
Data Analytics Emerges as Value Leader
According to the analysis, data analytics stocks appear to be the most undervalued group, a trend attributed to market fears surrounding the ad-tech industry and the potential for AI to disrupt existing business models. This subsector trades at an average price-to-sales (P/S) multiple of approximately 2.0x and an average enterprise value to EBITDA (EV/EBITDA) multiple of around 8x.
These multiples are significantly lower than those of other software categories. The analysis highlighted several companies with notable valuation metrics, including:
- The Trade Desk (TTD): Trading at 8.1x EV/EBITDA despite a year-to-date performance decline of -60.6%.
- Teradata (TDC): Valued at 1.5x P/S and 6.6x EV/EBITDA.
- DoubleVerify (DV): Valued at 2.7x P/S and 13.8x EV/EBITDA.
Infrastructure and SaaS Command Higher Premiums
AdIn contrast, infrastructure software and Software-as-a-Service (SaaS) business applications carry richer valuations. Infrastructure software, known for its reliable cash flows, has seen its multiples hold up better, resulting in what the analysis calls "thinner relative value."
This segment trades at an average P/S of ~3.4x and an EV/EBITDA of ~11x. The SaaS application group, which includes high-profile names like Salesforce and Zoom, is priced highest of all, with an average P/S of ~4.7x and an EV/EBITDA of ~17x. One standout in the SaaS category was Adobe (ADBE), which the analysis noted as having the group's lowest EV/EBITDA multiple at 10.4x following a recent sell-off.
Market Perspective and Risks
The valuation disparity is stark: data analytics stocks are trading at P/S multiples less than half those of SaaS companies, with a nearly 50% discount on an EV/EBITDA basis. The analysis suggests that investor fears over AI commoditizing data processing have been aggressively priced into stocks like TTD and Teradata.
However, this lower valuation comes with a key risk. The bear case, as noted in the source, is that if AI genuinely diminishes the value of existing data processing and measurement platforms, then the current low multiples may be justified. For investors seeking a more defensive profile, infrastructure software's mission-critical nature may offer a more stable alternative.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.

Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.

Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.

Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.